Corporate Banner
Satellite Banner
Biomolecular Screening
Scientific Community
Become a Member | Sign in
Home>News>This Article

Oncodesign Signs Partnership Agreement with Sanofi

Published: Thursday, March 28, 2013
Last Updated: Thursday, March 28, 2013
Bookmark and Share
Oncodesign will apply its Nanocyclix(R) technology to one of Sanofi's kinase targets.

Oncodesign announces that it has signed a second research collaboration agreement with Sanofi.

This partnership follows a first agreement signed in summer 2012, relating to a number of kinase targets being developed by Sanofi. This second agreement aims to identify inhibitors of a kinase which plays a key role in tissue protection and repair. Oncodesign will use its Nanocyclix(R) technology to design and synthesize potent new selective inhibitors. Sanofi will have exclusive licensing rights to the molecules that result from the collaboration.

Nanocyclix is a proprietary medicinal chemistry technology and a research platform based on a chemical macrocyclization process. The kinase inhibitors obtained using this process are potent and highly selective, because their structures demonstrate exceptional shape complementarity with the binding site of the kinase ATP (adenosine triphosphate). The resulting selectivity is unparalleled, especially for kinases that are highly homologous. Drawing on proven expertise, the technology also allows the pharmacokinetic properties of Nanocyclix compounds to be enhanced at an increased rate. Oncodesign leads the field in macrocyclic kinase inhibitors, offering partnership opportunities based on its own research programs and partners' programs that target the kinases to which the Nanocyclix technology is applied.

“This new agreement with Sanofi demonstrates the level of interest in our Nanocyclix technology from some of the most well-renowned pharma companies. This is our third collaboration agreement in a year of drug discovery, establishing our company as a leader in the field of kinase inhibitors in a variety of therapeutic areas,” says Dr Philippe Genne, chairman, CEO and founder of Oncodesign.

Under the terms of the agreement, Oncodesign will apply its Nanocyclix technology to a key target implicated in the therapeutic area of tissue protection and repair. The cost of the initial phase of the work is to be met in full by Sanofi, who will have exclusive rights to the results of the program. The financial details have not been disclosed.

Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,500+ scientific posters on ePosters
  • More than 5,100+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Oncodesign Enters into a Services Agreement with Eisai
The program aims to identify useful patient stratification biomarkers for Eisai’s Halaven® eribulin using patient-derived xenograft models.
Friday, December 26, 2014
Oncodesign and Banook Central Imaging Sign a Collaboration Agreement
The global reaching partnership aims to provide clinical researchers with new biomarkers and validated image analysis protocols, ensuring a continuum from preclinical to clinical phase in the development of anticancer therapies.
Tuesday, September 10, 2013
Oncodesign and OSEO Announce Funding of EUR 13.4 Million
This private-public partnership project, which aims to put in place the first national subsidiary dedicated to personalized medicine in oncology, has a EUR 41 million overall investment budget.
Tuesday, March 12, 2013
Scientific News
Mass Spec Technology Drives Innovation Across the Biopharma Workflow
With greater resolving power, analytical speed, and accuracy, new mass spectrometry technology and techniques are infiltrating the biopharmaceuticals workflow.
Less Frequent Cervical Cancer Screening
HPV-vaccinated women may only need one screening every 5 to 10 years with screening starting later in life.
Targeting Cannabinoid CB2 Receptors in the CNS
With endogenous cannabinoids considered as a potential target to combat CNS diseases, this article examines the role of CB2R could play in fighting some disorders.
Bacterial Genes Boost Current in Human Cells
Borrowing and tweaking bacterial genes to enhance electrical activity might treat heart, nervous system injury.
Cocoa Compound Linked to Some Cardiovascular Biomarker Improvements
The study highlights the urgent need for large, long-term RCTs that improve understanding of how the short-term benefits of cocoa flavanol intake on cardiometabolic biomarkers may be translated into clinical outcomes.
Untangling a Cause of Memory Loss in Neurodegenerative Diseases
The mouse study identifies a possible therapeutic target for a family of disorders.
New Pathway for COPD Biomarker Development
A study from Philip Morris International has highlighted multi-lipid profiling as a potential new pathway for COPD biomarker development.
Stiffening a Blow to Cancer Cells
Researchers develop a way to predict how a tumor tissue's physical properties affect its response to chemotherapy drugs.
Anti-Cancer Drug Uses Tumour mRNA to Identify Responders
Phase I study of novel anti-cancer drug uses tumour mRNA expression to identify patients who will respond to the drug.
New Strategy for Choosing Cancer Drugs
Device can predict tumor responses by measuring cell growth after drug exposure.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,100+ scientific videos